Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KK2845 in Relapsed or Refractory Acute Myeloid Leukemia and Other Hematologic Malignancies
NCT06812104Phase 1Recruiting
- Sponsor
- Kyowa Kirin
- Start
- Oct 2024
- Primary completion
- Nov 2031
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label trial of KK2845_3 in acute myeloid leukemia (AML) and hematologic malignancy (16 arms), sponsored by Kyowa Kirin. Primary endpoint: Dose-limiting toxicity. Started Oct 2024; status: recruiting.
02
Drugs
KK2845_3
03
Conditions
acute myeloid leukemia (AML)hematologic malignancy
Beyond the preview
Go deeper on NCT06812104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06812104.